This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okuno, S. H. Articles by Jett, J. R. Search for Related Content PubMed PubMed Citation Articles by Okuno, S. H. Articles by Jett, J. R.

Small Cell Lung Cancer: Current Therapy and Promising New Regimens

Mayo Clinic, Rochester, Minnesota, USA

Correspondence: Scott H. Okuno, M.D., Mayo Clinic, Rochester, Minnesota 55905, USA. Telephone: 507-284-2511; Fax: 507-284-1803; e-mail: okuno.scott{at}mayo.edu

In this review, we cover current therapy and promising new regimens and highlight areas where improvement is needed in the management of small cell lung cancer.

Key Words. Small cell • Lung cancer • Chemotherapy • Radiation

This article has been cited by other articles:

				A. R. Shoemaker, M. J. Mitten, J. Adickes, S. Ackler, M. Refici, D. Ferguson, A. Oleksijew, J. M. O'Connor, B. Wang, D. J. Frost, et al. Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models Clin. Cancer Res., June 1, 2008; 14(11): 3268 - 3277. [Abstract] [Full Text] [PDF]

				J. R. Eckardt, J. von Pawel, J.-L. Pujol, Z. Papai, E. Quoix, A. Ardizzoni, R. Poulin, A. J. Preston, G. Dane, and G. Ross Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer J. Clin. Oncol., May 20, 2007; 25(15): 2086 - 2092. [Abstract] [Full Text] [PDF]

				S. K. Tahir, X. Yang, M. G. Anderson, S. E. Morgan-Lappe, A. V. Sarthy, J. Chen, R. B. Warner, S.-C. Ng, S. W. Fesik, S. W. Elmore, et al. Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737 Cancer Res., February 1, 2007; 67(3): 1176 - 1183. [Abstract] [Full Text] [PDF]

				A. Ardizzoni Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update Oncologist, December 1, 2004; 9(suppl_6): 4 - 13. [Abstract] [Full Text] [PDF]

				J. R. Eckardt Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer Oncologist, December 1, 2004; 9(suppl_6): 25 - 32. [Abstract] [Full Text] [PDF]

				D. J. Stewart Topotecan in the First-Line Treatment of Small Cell Lung Cancer Oncologist, December 1, 2004; 9(suppl_6): 33 - 42. [Abstract] [Full Text] [PDF]

				R. E. Merritt, A. Mahtabifard, R. E. Yamada, R. G. Crystal, and R. J. Korst Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1609 - 1617. [Abstract] [Full Text] [PDF]

				G. M.M. Videtic, L. W. Stitt, A. R. Dar, W. I. Kocha, A. T. Tomiak, P. T. Truong, M. D. Vincent, and E. W. Yu Continued Cigarette Smoking by Patients Receiving Concurrent Chemoradiotherapy for Limited-Stage Small-Cell Lung Cancer Is Associated With Decreased Survival J. Clin. Oncol., April 15, 2003; 21(8): 1544 - 1549. [Abstract] [Full Text] [PDF]